receptor tyrosine kinase
/ ree-SEP-ter TY-roh-seen KY-nayss /
Imagine two halves of a walkie-talkie that only work when they snap together. Apart, each half is silent. But when the right person grabs both and clicks them into a pair, the device springs to life and starts broadcasting. A receptor tyrosine kinase behaves like that: the receptors sit quietly and separately in the membrane until a ligand brings two of them together, and only when they pair up does the signal switch on.
A receptor tyrosine kinase, or RTK, is a cell-surface receptor that is also an enzyme. Its inner part is a kinase — a tool that attaches phosphate tags to the amino acid tyrosine on proteins. When a ligand (often a growth factor) binds, two receptor molecules pair up (dimerize), and once paired they tag each other with phosphates in a process called autophosphorylation. Those new phosphate tags become docking sites: a crowd of internal signaling proteins recognizes them and assembles on the receptor's tail, launching several pathways at once — frequently including the MAP kinase pathway that drives cell growth and division.
RTKs matter enormously because they carry the signals that tell cells to grow, divide, and survive — exactly the signals a cancer would love to fake. Many tumors arise from an RTK that is mutated to stay paired and 'on' even with no ligand present, screaming 'divide' nonstop. This also makes RTKs prized drug targets: medicines like trastuzumab and many '-tinib' kinase inhibitors work by shutting overactive RTKs down. A common misconception is that an RTK passes its message to a G protein the way a GPCR does; in fact an RTK is its own enzyme and builds a signaling complex directly on itself, with no G protein in between.
In some breast cancers the RTK called HER2 is over-made and stays paired and active, constantly ordering the cell to divide. The drug trastuzumab (Herceptin) binds HER2 and blunts this stuck signal — a clear case of a signaling protein being both the disease and the cure's target.
A stuck-on growth-signal receptor can drive cancer — and become a drug target.
An RTK is its own enzyme and builds its signaling complex directly on itself — there is no G protein in between, unlike a GPCR. Most RTKs must pair up (dimerize) before they can fire.